Leiras Finland is seeking late stage (phase III onwards) prescription products in the following therapeutic indications; respiratory diseases, pain management, oncology diseases, cardiovascular health and metabolic diseases.
The company wishes to in-license the products into the four major Nordic countries. Any drugs to be considered should adhere to the following requirements;
1) Should have undergone phase II clinical trials, be NDA ready/submitted or marketing authorization
2) Should not require participation from Takeda/ commitment on new clinical trials
3) Serves an unmet medical need
4) Has patent coverage available for many years
5) Is directed mainly to a specialist
6) Be delivered in complete final packages and undergo release in the EU by a supplier
Leiras Finland is looking to in-license any potential candidates.